市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Nuvation Bio Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 价值 35% | 0.0 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | 0.0 |
| 时机 35% | -0.1 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | -2.5 |
| 技术平均移动指标 参考 | 3.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.21 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -22.4% |
| 支柱一致性 | ×1.00 |
| 不计入评分 | |
| 价格波动 参考 | 1.0 |
| 最终评分 | -0.04 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 19.14% |
| 机构持股比例 | 62.26% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Decheng Capital Llc | 30 Jun 2026 | 25,954,439 |
| Omega Fund Management, Llc | 30 Jun 2026 | 8,081,089 |
| Tang Capital Management Llc | 30 Jun 2026 | 3,299,557 |
该时间范围内无数据。
该时间范围内无数据。
投资组合